China Renal Cell Cacinoma Drugs Market Research Report 2017

December 2017 | 106 pages | ID: CCCFD7A166EEN
QYResearch

Abstracts

The global Renal Cell Cacinoma Drugs market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

China plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of xx%.

This report studies the Renal Cell Cacinoma Drugs development status and future trend in China, focuses on top players in China, also splits Renal Cell Cacinoma Drugs by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.

The major players in China market include

• Merck & Co., Inc.
• Exelixis Inc
• Argus Therapeutics, Inc.
• Bristol-Myers Squibb
• Genentech
• Immatics Biotechnologies
• AVEO Oncology
• Eisai
• Acceleron
• Rexahn Pharmaceuticals
• Bionomics
• Cerulean Pharma Inc
• Celldex Therapeutics
• TVAX Biomedical
• TRACON Pharmaceuticals

Geographically, this report splits the China market into six regions,

• South China
• East China
• Southwest China
• Northeast China
• North China
• Central China
• Northwest China

On the basis of product, this report displays the sales volume (K Pcs), revenue (Million USD), product price (USD/Pcs), market share and growth rate of each type, primarily split into

• Sutent(Sunitinib)
• Nexavar(Sorafenib)
• Votrient(Pazopanib)
• Avastin(Bevacizumab)
• Afinitor(Everolimus)
• Inlyta(Axitinib)
• Torisel(Temsirolimus)
• Proleukin(Aldesleukin)

On the basis of the end users/application, this report covers

• Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
• Multilocular Cystic Clear Cell Renal Cell Carcinoma
• Tubulocystic Renal Cell Carcinoma
• Thyroid-Like Follicular Renal Cell Carcinoma
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

China Renal Cell Cacinoma Drugs Market Research Report 2017

1 RENAL CELL CACINOMA DRUGS OVERVIEW

1.1 Product Overview and Scope of Renal Cell Cacinoma Drugs
1.2 Classification of Renal Cell Cacinoma Drugs by Product Category
  1.2.1 China Renal Cell Cacinoma Drugs Sales (K Pcs) Comparison by Type (2012-2022)
  1.2.2 China Renal Cell Cacinoma Drugs Sales (K Pcs) Market Share by Type in 2016
  1.2.3 Sutent(Sunitinib)
  1.2.4 Nexavar(Sorafenib)
  1.2.5 Votrient(Pazopanib)
  1.2.6 Avastin(Bevacizumab)
  1.2.7 Afinitor(Everolimus)
  1.2.8 Inlyta(Axitinib)
  1.2.9 Torisel(Temsirolimus)
  1.2.10 Proleukin(Aldesleukin)
1.3 China Renal Cell Cacinoma Drugs Market by Application/End Users
  1.3.1 China Renal Cell Cacinoma Drugs Sales (K Pcs) and Market Share Comparison by Applications (2012-2022)
  1.3.2 Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
  1.3.3 Multilocular Cystic Clear Cell Renal Cell Carcinoma
  1.3.4 Tubulocystic Renal Cell Carcinoma
  1.3.5 Thyroid-Like Follicular Renal Cell Carcinoma
  1.3.6 Others
1.4 China Renal Cell Cacinoma Drugs Market by Region
  1.4.1 China Renal Cell Cacinoma Drugs Market Size (Million USD) Comparison by Region (2012-2022)
  1.4.2 South China Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
  1.4.3 East China Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
  1.4.4 Southwest China Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
  1.4.5 Northeast China Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
  1.4.6 North China Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
  1.4.7 Central China Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
1.5 China Market Size (Sales and Revenue) of Renal Cell Cacinoma Drugs (2012-2022)
  1.5.1 China Renal Cell Cacinoma Drugs Sales (K Pcs) and Growth Rate (%)(2012-2022)
  1.5.2 China Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate (%)(2012-2022)

2 CHINA RENAL CELL CACINOMA DRUGS MARKET COMPETITION BY PLAYERS/MANUFACTURERS

2.1 China Renal Cell Cacinoma Drugs Sales and Market Share of Key Players/Manufacturers (2012-2017)
2.2 China Renal Cell Cacinoma Drugs Revenue and Share by Players/Manufacturers (2012-2017)
2.3 China Renal Cell Cacinoma Drugs Average Price (USD/Pcs) by Players/Manufacturers (2012-2017)
2.4 China Renal Cell Cacinoma Drugs Market Competitive Situation and Trends
  2.4.1 China Renal Cell Cacinoma Drugs Market Concentration Rate
  2.4.2 China Renal Cell Cacinoma Drugs Market Share of Top 3 and Top 5 Players/Manufacturers
  2.4.3 Mergers & Acquisitions, Expansion in China Market
2.5 China Players/Manufacturers Renal Cell Cacinoma Drugs Manufacturing Base Distribution, Sales Area, Product Types

3 CHINA RENAL CELL CACINOMA DRUGS SALES AND REVENUE BY REGION (2012-2017)

3.1 China Renal Cell Cacinoma Drugs Sales (K Pcs) and Market Share by Region (2012-2017)
3.2 China Renal Cell Cacinoma Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
3.3 China Renal Cell Cacinoma Drugs Price (USD/Pcs) by Regions (2012-2017)

4 CHINA '&B1&' SALES AND REVENUE BY TYPE/ PRODUCT CATEGORY (2012-2017)'

4.1 China Renal Cell Cacinoma Drugs Sales (K Pcs) and Market Share by Type/ Product Category (2012-2017)
4.2 China Renal Cell Cacinoma Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
4.3 China Renal Cell Cacinoma Drugs Price (USD/Pcs) by Type (2012-2017)
4.4 China Renal Cell Cacinoma Drugs Sales Growth Rate (%) by Type (2012-2017)

5 CHINA '&B1&' SALES BY APPLICATION (2012-2017)'

5.1 China Renal Cell Cacinoma Drugs Sales (K Pcs) and Market Share by Application (2012-2017)
5.2 China Renal Cell Cacinoma Drugs Sales Growth Rate (%) by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 CHINA RENAL CELL CACINOMA DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Merck & Co., Inc.
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Merck & Co., Inc. Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Exelixis Inc
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Exelixis Inc Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Argus Therapeutics, Inc.
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Bristol-Myers Squibb
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Bristol-Myers Squibb Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Genentech
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Genentech Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Immatics Biotechnologies
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Immatics Biotechnologies Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.6.4 Main Business/Business Overview
6.7 AVEO Oncology
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 AVEO Oncology Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Eisai
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Eisai Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Acceleron
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Acceleron Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Rexahn Pharmaceuticals
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Bionomics
6.12 Cerulean Pharma Inc
6.13 Celldex Therapeutics
6.14 TVAX Biomedical
6.15 TRACON Pharmaceuticals

7 RENAL CELL CACINOMA DRUGS MANUFACTURING COST ANALYSIS

7.1 Renal Cell Cacinoma Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Renal Cell Cacinoma Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Renal Cell Cacinoma Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Renal Cell Cacinoma Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 CHINA RENAL CELL CACINOMA DRUGS MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

11.1 China Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
11.2 China Renal Cell Cacinoma Drugs Sales (K Pcs) Forecast by Type (2017-2022)
11.3 China Renal Cell Cacinoma Drugs Sales (K Pcs) Forecast by Application (2017-2022)
11.4 China Renal Cell Cacinoma Drugs Sales (K Pcs) Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 METHODOLOGY AND DATA SOURCE

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Global and China Market Size (Million USD) Comparison (2012-2022)
Table Renal Cell Cacinoma Drugs Sales (K Pcs) and Revenue (Million USD) Market Split by Product Type
Table Renal Cell Cacinoma Drugs Sales (K Pcs) by Application (2016-2022)
Figure Product Picture of Renal Cell Cacinoma Drugs
Table China Renal Cell Cacinoma Drugs Sales (K Pcs) and Growth Rate (%) Comparison by Types (Product Category) (2012-2022)
Figure China Renal Cell Cacinoma Drugs Sales Volume Market Share by Types in 2016
Figure Sutent(Sunitinib) Product Picture
Figure Nexavar(Sorafenib) Product Picture
Figure Votrient(Pazopanib) Product Picture
Figure Avastin(Bevacizumab) Product Picture
Figure Afinitor(Everolimus) Product Picture
Figure Inlyta(Axitinib) Product Picture
Figure Torisel(Temsirolimus) Product Picture
Figure Proleukin(Aldesleukin) Product Picture
Figure China Renal Cell Cacinoma Drugs Sales (K Pcs) Comparison by Application (2012-2022)
Figure China Sales Market Share (%) of Renal Cell Cacinoma Drugs by Application in 2016
Figure Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) Examples
Table Key Downstream Customer in Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
Figure Multilocular Cystic Clear Cell Renal Cell Carcinoma Examples
Table Key Downstream Customer in Multilocular Cystic Clear Cell Renal Cell Carcinoma
Figure Tubulocystic Renal Cell Carcinoma Examples
Table Key Downstream Customer in Tubulocystic Renal Cell Carcinoma
Figure Thyroid-Like Follicular Renal Cell Carcinoma Examples
Table Key Downstream Customer in Thyroid-Like Follicular Renal Cell Carcinoma
Figure Others Examples
Table Key Downstream Customer in Others
Figure South China Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure East China Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest China Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Northeast China Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure North China Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Central China Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure China Renal Cell Cacinoma Drugs Sales (K Pcs) and Growth Rate (%)(2012-2022)
Figure China Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate (%)(2012-2022)
Table China Renal Cell Cacinoma Drugs Sales of Key Players/Manufacturers (2012-2017)
Table China Renal Cell Cacinoma Drugs Sales Share (%) by Players/Manufacturers (2012-2017)
Figure 2016 China Renal Cell Cacinoma Drugs Sales Share (%) by Players/Manufacturers
Figure 2017 China Renal Cell Cacinoma Drugs Sales Share (%) by Players/Manufacturers
Table China Renal Cell Cacinoma Drugs Revenue by Players/Manufacturers (2012-2017)
Table China Renal Cell Cacinoma Drugs Revenue Market Share (%) by Players/Manufacturers (2012-2017)
Figure 2016 China Renal Cell Cacinoma Drugs Revenue Market Share (%) by Players/Manufacturers
Figure 2017 China Renal Cell Cacinoma Drugs Revenue Market Share (%) by Players/Manufacturers
Table China Market Renal Cell Cacinoma Drugs Average Price of Key Players/Manufacturers (2012-2017)
Figure China Market Renal Cell Cacinoma Drugs Average Price of Key Players/Manufacturers in 2016
Figure China Renal Cell Cacinoma Drugs Market Share of Top 3 Players/Manufacturers
Figure China Renal Cell Cacinoma Drugs Market Share of Top 5 Players/Manufacturers
Table China Players/Manufacturers Renal Cell Cacinoma Drugs Manufacturing Base Distribution and Sales Area
Table China Players/Manufacturers Renal Cell Cacinoma Drugs Product Category
Table China Renal Cell Cacinoma Drugs Sales (K Pcs) by Regions (2012-2017)
Table China Renal Cell Cacinoma Drugs Sales Share (%) by Regions (2012-2017)
Figure China Renal Cell Cacinoma Drugs Sales Share (%) by Regions (2012-2017)
Figure China Renal Cell Cacinoma Drugs Sales Market Share (%) by Regions in 2016
Table China Renal Cell Cacinoma Drugs Revenue (Million USD) and Market Share by Regions (2012-2017)
Table China Renal Cell Cacinoma Drugs Revenue Market Share (%) by Regions (2012-2017)
Figure China Renal Cell Cacinoma Drugs Revenue Market Share (%) by Regions (2012-2017)
Figure China Renal Cell Cacinoma Drugs Revenue Market Share (%) by Regions in 2016
Table China Renal Cell Cacinoma Drugs Price (USD/Pcs) by Regions (2012-2017)
Table China Renal Cell Cacinoma Drugs Sales (K Pcs) by Type (2012-2017)
Table China Renal Cell Cacinoma Drugs Sales Share (%) by Type (2012-2017)
Figure China Renal Cell Cacinoma Drugs Sales Share (%) by Type (2012-2017)
Figure China Renal Cell Cacinoma Drugs Sales Market Share (%) by Type in 2016
Table China Renal Cell Cacinoma Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table China Renal Cell Cacinoma Drugs Revenue Market Share (%) by Type (2012-2017)
Figure Revenue Market Share of Renal Cell Cacinoma Drugs by Type (2012-2017)
Figure Revenue Market Share of Renal Cell Cacinoma Drugs by Type in 2016
Table China Renal Cell Cacinoma Drugs Price (USD/Pcs) by Types (2012-2017)
Figure China Renal Cell Cacinoma Drugs Sales Growth Rate (%) by Type (2012-2017)
Table China Renal Cell Cacinoma Drugs Sales (K Pcs) by Applications (2012-2017)
Table China Renal Cell Cacinoma Drugs Sales Market Share (%) by Applications (2012-2017)
Figure China Renal Cell Cacinoma Drugs Sales Market Share (%) by Application (2012-2017)
Figure China Renal Cell Cacinoma Drugs Sales Market Share (%) by Application in 2016
Table China Renal Cell Cacinoma Drugs Sales Growth Rate (%) by Application (2012-2017)
Figure China Renal Cell Cacinoma Drugs Sales Growth Rate (%) by Application (2012-2017)
Table Merck & Co., Inc. Renal Cell Cacinoma Drugs Basic Information List
Table Merck & Co., Inc. Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Merck & Co., Inc. Renal Cell Cacinoma Drugs Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Merck & Co., Inc. Renal Cell Cacinoma Drugs Sales Market Share (%) in China (2012-2017)
Figure Merck & Co., Inc. Renal Cell Cacinoma Drugs Revenue Market Share (%) in China (2012-2017)
Table Exelixis Inc Renal Cell Cacinoma Drugs Basic Information List
Table Exelixis Inc Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Exelixis Inc Renal Cell Cacinoma Drugs Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Exelixis Inc Renal Cell Cacinoma Drugs Sales Market Share (%) in China (2012-2017)
Figure Exelixis Inc Renal Cell Cacinoma Drugs Revenue Market Share (%) in China (2012-2017)
Table Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Basic Information List
Table Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Sales Market Share (%) in China (2012-2017)
Figure Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Revenue Market Share (%) in China (2012-2017)
Table Bristol-Myers Squibb Renal Cell Cacinoma Drugs Basic Information List
Table Bristol-Myers Squibb Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Bristol-Myers Squibb Renal Cell Cacinoma Drugs Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Bristol-Myers Squibb Renal Cell Cacinoma Drugs Sales Market Share (%) in China (2012-2017)
Figure Bristol-Myers Squibb Renal Cell Cacinoma Drugs Revenue Market Share (%) in China (2012-2017)
Table Genentech Renal Cell Cacinoma Drugs Basic Information List
Table Genentech Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Genentech Renal Cell Cacinoma Drugs Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Genentech Renal Cell Cacinoma Drugs Sales Market Share (%) in China (2012-2017)
Figure Genentech Renal Cell Cacinoma Drugs Revenue Market Share (%) in China (2012-2017)
Table Immatics Biotechnologies Renal Cell Cacinoma Drugs Basic Information List
Table Immatics Biotechnologies Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Immatics Biotechnologies Renal Cell Cacinoma Drugs Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Immatics Biotechnologies Renal Cell Cacinoma Drugs Sales Market Share (%) in China (2012-2017)
Figure Immatics Biotechnologies Renal Cell Cacinoma Drugs Revenue Market Share (%) in China (2012-2017)
Table AVEO Oncology Renal Cell Cacinoma Drugs Basic Information List
Table AVEO Oncology Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure AVEO Oncology Renal Cell Cacinoma Drugs Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure AVEO Oncology Renal Cell Cacinoma Drugs Sales Market Share (%) in China (2012-2017)
Figure AVEO Oncology Renal Cell Cacinoma Drugs Revenue Market Share (%) in China (2012-2017)
Table Eisai Renal Cell Cacinoma Drugs Basic Information List
Table Eisai Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Eisai Renal Cell Cacinoma Drugs Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Eisai Renal Cell Cacinoma Drugs Sales Market Share (%) in China (2012-2017)
Figure Eisai Renal Cell Cacinoma Drugs Revenue Market Share (%) in China (2012-2017)
Table Acceleron Renal Cell Cacinoma Drugs Basic Information List
Table Acceleron Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Acceleron Renal Cell Cacinoma Drugs Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Acceleron Renal Cell Cacinoma Drugs Sales Market Share (%) in China (2012-2017)
Figure Acceleron Renal Cell Cacinoma Drugs Revenue Market Share (%) in China (2012-2017)
Table Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Basic Information List
Table Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Sales Market Share (%) in China (2012-2017)
Figure Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Revenue Market Share (%) in China (2012-2017)
Table Bionomics Renal Cell Cacinoma Drugs Basic Information List
Table Cerulean Pharma Inc Renal Cell Cacinoma Drugs Basic Information List
Table Celldex Therapeutics Renal Cell Cacinoma Drugs Basic Information List
Table TVAX Biomedical Renal Cell Cacinoma Drugs Basic Information List
Table TRACON Pharmaceuticals Renal Cell Cacinoma Drugs Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Renal Cell Cacinoma Drugs
Figure Manufacturing Process Analysis of Renal Cell Cacinoma Drugs
Figure Renal Cell Cacinoma Drugs Industrial Chain Analysis
Table Raw Materials Sources of Renal Cell Cacinoma Drugs Major Players/Manufacturers in 2016
Table Major Buyers of Renal Cell Cacinoma Drugs
Table Distributors/Traders List
Figure China Renal Cell Cacinoma Drugs Sales (K Pcs) and Growth Rate (%) Forecast (2017-2022)
Figure China Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure China Renal Cell Cacinoma Drugs Price (USD/Pcs) Trend Forecast (2017-2022)
Table China Renal Cell Cacinoma Drugs Sales (K Pcs) Forecast by Type (2017-2022)
Figure China Renal Cell Cacinoma Drugs Sales (K Pcs) Forecast by Type (2017-2022)
Figure China Renal Cell Cacinoma Drugs Sales Volume Market Share Forecast by Type in 2022
Table China Renal Cell Cacinoma Drugs Sales (K Pcs) Forecast by Application (2017-2022)
Figure China Renal Cell Cacinoma Drugs Sales Volume Market Share Forecast by Application (2017-2022)
Figure China Renal Cell Cacinoma Drugs Sales Volume Market Share Forecast by Application in 2022
Table China Renal Cell Cacinoma Drugs Sales (K Pcs) Forecast by Regions (2017-2022)
Table China Renal Cell Cacinoma Drugs Sales Volume Share Forecast by Regions (2017-2022)
Figure China Renal Cell Cacinoma Drugs Sales Volume Share Forecast by Regions (2017-2022)
Figure China Renal Cell Cacinoma Drugs Sales Volume Share Forecast by Regions in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources